But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
The group looks like the gene therapy contender to beat, but that is not saying much.
Spac backtrack confirms that the gene therapy bubble has burst
Praxis, Proqr and Nordic Nanovector are awaiting important data.
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.